Flow cytometric immunophenotyping in fine-needle aspiration of lymph nodes

被引:10
作者
Chung, JG [1 ]
Gong, GY [1 ]
Huh, JY [1 ]
Khang, SK [1 ]
Ro, JY [1 ]
机构
[1] Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, Seoul, South Korea
关键词
lymphoproliferative disorders; flow cytometry; immunophenotyping; needle biopsy;
D O I
10.3346/jkms.1999.14.4.393
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fine-needle aspiration (FNA) of lymph nodes has been regarded as a useful method in the diagnosis of lymphadenopathy. However, this procedure has been shown to be of limited value in the diagnosis of low or intermediate grade malignant lymphomas in some studies. Immunophenotyping is an essential adjunct to cytomorphology for the diagnosis of lymphoma by FNA. Immunophenotyping using flow cytometry (FCM) is rapid, objective and reliable, Using FCM, multiparametric analysis of 33 FNA materials from lymph nodes was performed and profiles of surface markers of lymphoid cells were assessed. In reactive hyperplasia, patterns of cell surface markers were quite variable, but disclosed polyclonality. Most of the B-cell lymphomas showed immunophenotypes for B-cell lineages with their kappa: lambda or lambda: kappa ratio being over 3:1. In T-cell lymphomas, T-cell surface markers were predominantly expressed as well. In conclusion, our results suggest that immunophenotyping of lymph node aspirates is a valuable diagnostic adjunct for lymphoproliferative disorders, particularly in B-cell lymphomas because immunophenotyping can be easily and adequately performed by FCM.
引用
收藏
页码:393 / 400
页数:8
相关论文
共 50 条
[1]   LOCALIZATION OF MONOCLONAL B-CELL POPULATIONS THROUGH THE USE OF KOMOGOROV-SMIRNOV D-VALUE AND REDUCED CHI-SQUARE CONTOURS [J].
BAGWELL, CB ;
LOVETT, EJ ;
AULT, KA .
CYTOMETRY, 1988, 9 (05) :469-476
[2]   PROGNOSTIC IMPLICATIONS OF PLOIDY AND PROLIFERATIVE ACTIVITY IN HUMAN SOLID TUMORS [J].
BARLOGIE, B ;
JOHNSTON, DA ;
SMALLWOOD, L ;
RABER, MN ;
MADDOX, AM ;
LATREILLE, J ;
SWARTZENDRUBER, DE ;
DREWINKO, B .
CANCER GENETICS AND CYTOGENETICS, 1982, 6 (01) :17-28
[3]  
BETSILL WL, 1980, AM J CLIN PATHOL, V73, P471
[4]  
BIZJAKSCHWARZBARTL M, 1988, ACTA CYTOL, V32, P216
[5]  
BONFIGLIO TA, 1985, ACTA CYTOL, V29, P548
[6]  
Braylan R C, 1988, Cytometry Suppl, V3, P73
[7]  
BRAYLAN RC, 1985, BLOOD, V66, P185
[8]  
CAFFERTY LL, 1990, CANCER, V65, P72, DOI 10.1002/1097-0142(19900101)65:1<72::AID-CNCR2820650116>3.0.CO
[9]  
2-Q
[10]  
CARTER TR, 1988, ACTA CYTOL, V32, P848